Báo cáo khoa học: Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting pdf

MINIREVIEW
Roles of matrix metalloproteinases in cancer progression
and their pharmacological targeting
Chrisostomi Gialeli
1
, Achilleas D. Theocharis
1
and Nikos K. Karamanos
1,2
1 Department of Chemistry, Laboratory of Biochemistry, University of Patras, Greece
2 Institute of Chemical Engineering and High-Temperature Chemical Processes (FORTH ⁄ ICE-HT), Patras, Greece
Introduction
Cancer is one of the leading causes of disease and
mortality worldwide [1]. As a result, the past two dec-
ades of biomedical research have yielded an enormous
amount of information on the molecular events that
take place during carcinogenesis and the signaling
pathways participating in cancer progression. The
molecular mechanisms of the complex interplay
between the tumor cells and the tumor microenviron-
ment play a pivotal role in this process [2].
Studies conducted over more than 40 years have
revealed mounting evidence supporting that extracellu-
lar matrix remodeling proteinases, such as matrix
metalloproteinases (MMPs), are the principal media-
tors of the alterations observed in the microenviron-
ment during cancer progression [2,3]. MMPs belong to
a zinc-dependent family of endopeptidases implicated
in a variety of physiological processes, including
wound healing, uterine involution and organogenesis,
Keywords

angiogenesis; invasion and metastasis;
matrix metalloproteinase; matrix
metalloproteinase inhibitor; pharmacological
target
Correspondence
N. Karamanos, Laboratory of Biochemistry,
Department of Chemistry, University of
Patras, 26110 Patras, Greece
Fax: +30 2610 997153
Tel: +30 2610 997915
E-mail:
(Received 20 June 2010, revised 20 August
2010, accepted 18 October 2010)
doi:10.1111/j.1742-4658.2010.07919.x
Matrix metalloproteinases (MMPs) consist of a multigene family of zinc-
dependent extracellular matrix (ECM) remodeling endopeptidases implicated
in pathological processes, such as carcinogenesis. In this regard, their activity
plays a pivotal role in tumor growth and the multistep processes of invasion
and metastasis, including proteolytic degradation of ECM, alteration of the
cell–cell and cell–ECM interactions, migration and angiogenesis. The under-
lying premise of the current minireview is that MMPs are able to proteolyti-
cally process substrates in the extracellular milieu and, in so doing, promote
tumor progression. However, certain members of the MMP family exert con-
tradicting roles at different stages during cancer progression, depending
among other factors on the tumor stage, tumor site, enzyme localization and
substrate profile. MMPs are therefore amenable to therapeutic intervention
by synthetic and natural inhibitors, providing perspectives for future studies.
Multiple therapeutic agents, called matrix metalloproteinase inhibitors
(MMPIs) have been developed to target MMPs, attempting to control their
enzymatic activity. Even though clinical trials with these compounds do not

show the expected results in most cases, the field of MMPIs is ongoing. This
minireview critically evaluates the role of MMPs in relation to cancer pro-
gression, and highlights the challenges, as well as future prospects, for the
design, development and efficacy of MMPIs.
Abbreviations
ADAM, a disintegrin and metalloproteinase; ADAMTS, a disintegrin and metalloproteinase with thrombospondin motifs; bFGF, basic
fibroblast growth factor; ECM, extracellular matrix; EGFR, epidermal growth factor receptor; EMT, epithelial to mesenchymal transition;
GAG, glycosaminoglycan; HB-EGF, heparin-binding epidermal growth factor; IGF, insulin-like growth factor; MMP, matrix metalloproteinase;
MMPI, metalloproteinase inhibitor; MT-MMP, membrane-type matrix metalloproteinase; NK, natural killer; siRNA, small interfering RNA;
TGF, transforming growth factor; TIMP, tissue inhibitor of metalloproteinase; VEGF, vascular endothelial growth factor.
16 FEBS Journal 278 (2011) 16–27 ª 2010 The Authors Journal compilation ª 2010 FEBS
as well as in pathological conditions, such as inflamma-
tory, vascular and auto-immune disorders, and carcino-
genesis [3–6]. MMPs have been considered as potential
diagnostic and prognostic biomarkers in many types
and stages of cancer [7]. The notion of MMPs as thera-
peutic targets of cancer was introduced 25 years ago
because the metastatic potential of various cancers was
correlated with the ability of cancer cells to degrade the
basement membrane [8]. Subsequently, a growing num-
ber of MMP inhibitors (MMPIs) have been developed
and evaluated in several clinical trials.
A zinc-dependent family of proteinases related to
the MMPs is represented by a disintegrin and metallo-
proteinase (ADAM), which includes two subgroups:
the membrane-bound ADAM and a disintegrin and
metalloproteinase with thrombospondin motifs (AD-
AMTS). Recent studies show that ADAM and AD-
AMTS present altered expression in diverse tumor
types, suggesting that these proteins are involved in

different steps of cancer progression including carcino-
genesis [9,10]. ADAM molecules are implicated in
tumor cell prolireration ⁄ apoptosis, cell adhe-
sion ⁄ migration and cell signaling. In particular, they
exhibit proteolytic activity like MMPs, although their
main roles focus on ectodomain shedding and nonpro-
teolytic functions, such as binding to adhesion mole-
cules, integrins and interacting with phosphorylation
sites for serine ⁄ threonine and tyrosine kinases, thus
contributing to cancer development [11].
Roles of MMPs in cancer progression
During development of carcinogenesis, tumor cells
participate in several interactions with the tumor
microenvironment involving extracellular matrix
(ECM), growth factors and cytokines associated with
ECM, as well as surrounding cells (endothelial cells,
fibroblasts, macrophages, mast cells, neutrophils,
pericytes and adipocytes) [2,10,12]. Four hallmarks of
cancer that include migration, invasion, metastasis and
angiogenesis are dependent on the surrounding micro-
environment. Critical molecules in these processes are
MMPs because they degrade various cell adhesion
molecules, thereby modulating cell–cell and cell–ECM
interactions (Fig. 1). Key MMPs in relation to the
stages of cancer progression, their activity and their
effects are summarized in Table 1, as they are depicted
in the text.
The emerging view, reflected by several studies,
reveals that the expression and role of MMPs and
their natural inhibitors [i.e. tissue inhibitor of metallo-

proteinases (TIMP)] is quite diverse during cancer
development. The over-expression of MMPs in the
tumor microenvironment depends not only on the can-
cer cells, but also on the neighboring stromal cells,
which are induced by the cancer cells in a paracrine
manner. Cancer cells stimulate host cells such as fibro-
blasts to constitute an important source of MMPs
through the secretion of interleukins and growth fac-
tors and direct signaling through extracellular MMP
inducer [10]. The cellular source of MMPs can there-
fore have critical consequences on their function and
activity. For example, in this regard, neutrophils
express MMP-9 free of TIMP-1, which results in acti-
vation of the proteinase more readily [13].
Recent studies show that members of the MMP
family exert different roles at different stages during
cancer progression. In particular, they may promote or
inhibit cancer development depending among other
factors on the tumor stage, tumor site (primary, metas-
tasis), enzyme localization (tumor cells, stroma) and
substrate profile. For example, MMP-8 provides a pro-
tective effect in the metastatic process, decreasing the
metastatic potential of breast cancer cells when it is
over-expressed [14]. Similarly, MMP-8 expression in
squamous cell carcinoma of the tongue is correlated
with improved survival of patients and it is proposed
that this protective action is probably correlated with
the role of estrogen in the growth of tongue squamous
cell carcinomas [12,15]. On the other hand, MMP-9
might function as tumor promoter in the process of

carcinogenesis as well as an anticancer enzyme at later
stages of the disease in some specific situations. This
dual role is based on the findings in animal models,
where it observed that MMP-9 knockdown mouse
models exhibited decreased incidence of carcinogenesis,
whereas tumors formed in MMP-9 deficient mice were
significantly more aggressive [12].
Similarly, ADAMTS exhibits some contradictive
outcomes because ADAMTS-12 and ADAMTS-1 dis-
play anti-angiogenic and antimetastatic properties. One
possible explanation to consider, especially for
ADAMTS-1, is that this molecule undergoes auto-pro-
teolytic cleavage or even proteolytically impairment of
its catalytic site that can account for these outcomes
[11,16]. In both cases, the story will mature over the
next few years because much research is in progress
within this field.
MMPs and cancer cell invasion
The ECM is a dynamic structure that orchestrates the
behavior of the cells by interacting with them. The
proteolytic activity of MMPs is required for a cancer
cell to degrade physical barriers during local expansion
and intravasation at nearby blood vessels, extravasation
C. Gialeli et al. MMPs as potential targets in malignancy
FEBS Journal 278 (2011) 16–27 ª 2010 The Authors Journal compilation ª 2010 FEBS 17
and invasion at a distant location (Fig. 1). During
invasion, the localization of MMPs to specialized cell
surface structures, called invadopodia, is requisite for
their ability to promote invasion. These structures rep-
resent the site where active ECM degradation takes

place. Invadopodia utilize transmembrane invadopodi-
a-related proteinases, including MMP-14 [membrane-
type (MT)1-MMP], several members of the ADAM
family, as well as secreted and activated MMPs at the
site, such as MMP-2 and -9, to degrade a variety of
ECM macromolecules and facilitate cell invasion [17].
The contribution of MMP activities to several critical
steps of cancer progression is described below.
MMPs and cancer cell proliferation
There are several mechanisms by which MMPs con-
tribute to tumor cell proliferation. In particular, they
can modulate the bioavailability of growth factors and
the function of cell-surface receptors. The above pro-
cess also involves the ADAM family. Members of the
MMP and ADAM families can release the cell-mem-
brane-precursors of several growth factors, such as
insulin-like growth factors (IGFs) and the epidermal
growth factor receptor (EGFR) ligands that promote
proliferation. Several MMPs (MMP-1, -2, -3, -7, -9,
-11 and -19) and ADAM12 cleave IGF-binding
Fig. 1. Pivotal roles of MMPs in cancer progression. Cancer progression involves different stages, including tumor growth and the multistep
processes of invasion, metastasis and angiogenesis, all of which can be modulated by MMPs. The expression of MMPs in the tumor micro-
environment depends not only on the cancer cells, but also on the neighboring stromal cells. MMPs exert their proteolytic activity and
degrade the physical barriers, facilitating angiogenesis, tumor cells invasion and metastasis. Tumor growth and angiogenesis also depend on
the increased availability of signaling molecules, such as growth factors and cytokines, by MMPs making these factors more accessible to
the cancer cells and the tumor microenvironment. This occurs by liberating them from the ECM (IGF, bFGF and VEGF) or by shedding them
by from the cell surface (EGF, TGF-a, HB-EGF). Angiogenesis is also tightly modulated by the release of negative regulators of angiogenesis,
such as angiostatin, tumstatin, endostatin and endorepellin. MMPs also modulate the cell–cell and cell–ECM interactions by processing
E-cadherin and integrins, respectively, affecting both cell phenotype (EMT) and increasing cell migration.
MMPs as potential targets in malignancy C. Gialeli et al.

18 FEBS Journal 278 (2011) 16–27 ª 2010 The Authors Journal compilation ª 2010 FEBS
proteins that regulate the bioavailability of the growth
factor [18,19]. EGFR, mediator of cell proliferation, is
implicated in cancer progression because it is over-
expressed in more than one-third of all solid tumors
[20]. During cancer progression, increased shedding of
the membrane-anchored ligands of EGFR, including
heparin-binding EGF (HB-EGF), transforming growth
factor (TGF)-a and amphiregulin, was observed with
the action of MMP-3, -7, ADAM17 or ADAM10
[21,22]. MMPs and ADAM also control proliferation
signals through integrins because the shedding of
E-cadherin results in b-catenin translocation to the
nucleus, leading to cell proliferation [23]. It is worth
noting that the inactive proform of TGF-b, an impor-
tant biomolecule in cancer, is proteolytically activated
by MMP-9, -2, -14 in a similar way [24,25].
One of the key observations that has emerged from
several studies is the pivotal role of the interactions
between glycosaminoglycans (GAGs)-MMPs-GFs,
leading to the activation of the proMMPs and their
Table 1. Key matrix metalloproteinases in relation with the stages of cancer progression, their activity and effect.
MMP Activity Effect
Cancer cell invasion
Several MMPs such as MT1-MMP,
MMP-2 and MMP-9
Proteolytic Degrade physical barriers
Several members of the ADAM family
Cancer cell proliferation
MMP-1, -2, -3, -7, -9, -11, -19, ADAM12 Cleavage of IGF-binding proteins Proliferation

MMP-3, -7, ADAM17, ADAM10 Shedding of membrane-anchored ligands of EGFR
(HB-EGF, TGF-a and amphiregulin)
ADAM10 Shedding of E-cadherin
MMP-9, -2, -14 Activation of TGF-b
MMP-7 (anchored to CD44) Shedding of HB-EGF
Cancer cell apoptosis
MMP-7, ADAM10 Cleavage of Fas ligand Anti-apoptotic
ADAM10 Shedding of tumor associated major
histocompatibility proteins complex class-I
Several MMPs and ADAMs Indirect activation of Akt through activation of
EGFR and IGFR
Tumor angiogenesis and vasculogenesis
Several MMPs (including MMP-2,
-9 MMP-3, -10, -11 MMP-1, -8, -13)
Degradation of COL-IV, perlecan; release of VEGF
and bFGF, respectively
Up-regulation of angiogenesis
Degradation of COL-IV, COL-XVIII, perlecan;
generation of tumstatin, endostatin, angiostatin
and endorepellin, respectively
Down-regulation of angiogenesis
Cell adhesion, migration, and epithelial to mesenchymal transition
MMP-2 Degradation of COL-IV; generation of cryptic
peptides
Promote migration
MT1-MMP Degradation of laminin-5; generation of cryptic
peptides
MMPs Integrins as substrates
MMP-2, -3, -9, -13, -14 Over-expression; related to EMT Induction of EMT; cell migration
ADAM10

MMP-1, -7
Shedding of E-cadherin
MMP-28 Proteolytic activation of TGF-b Powerful inducer of EMT;
cell migration
Immune surveillance
MMP-9 Shedding of interleukin-2 receptor-a by
T-lymphocytes surface
Suppress T-lymphocyte proliferation
MMP-9, -2, -14 Release of active TGF-b Suppress T-lymphocyte reaction
against cancer cells
MMP-7, -11, -1, -8, -3 Release of a1-proteinase inhibitor Decrease cancer cell sensitivity
to NK cells
MMP-7, -8 Cleavage of a- and b-chemokines or regulation
of their mobilization
Affect leukocyte infiltration
and migration
C. Gialeli et al. MMPs as potential targets in malignancy
FEBS Journal 278 (2011) 16–27 ª 2010 The Authors Journal compilation ª 2010 FEBS 19
subsequent proliferative effects. Notably, GAGs chains
can recruit MMPs to release growth factors from the
cell surface and, as a result, induce cancer cell prolifer-
ation. For example, MMP-7 exerts high affinity for
heparan sulfate chains. On the basis of this notion,
heparan sulfate chains on cell surface receptors, such
as some variant isoforms of CD44, anchor the proteo-
lytically active MMP-7, resulting in the cleavage of
HB-EGF [26]. The above findings may explain the
diverse proliferative outcomes of the various GAG
types in human malignant mesothelioma cell lines,
as well as indicating a structure–function relation-

ship [27].
MMPs and cancer cell apoptosis
Matrix-degrading enzymes confer both apoptotic and
anti-apoptotic actions. MMPs and ADAMs, especially
MMP-7 and ADAM10, confer anti-apoptotic signals
to cancer cells by cleaving Fas ligand, a transmem-
brane stimulator of the death receptor Fas, from the
cell surface. This proteolytic activity inactivates Fas
receptor and induces resistance to apoptosis and
chemoresistance to the cancer cells or promotes apop-
tosis to the neighboring cells depending on the system
[28–30]. Moreover, proteolytic shedding of tumor-
associated major histocompatibility proteins complex
class-I related proteins by ADAM17 may suppress
natural killer (NK) cell-mediated cytotoxicity toward
cancer cells [31]. Notably, MMPs may contribute to
the anti-apoptotic effect by activating indirectly the
serine ⁄ threonine kinase Akt ⁄ protein kinase B through
the signaling cascades of EGFR and IGFR [20,32].
MMPs also promote apoptosis, most likely indirectly
by changing the ECM composition; for exam-
ple, by cleaving laminin, which influences integrin
signaling [33].
MMPs and tumor angiogenesis and
vasculogenesis
MMPs display a dual role in tumor vasculature
because they can act both as positive and negative reg-
ulators of angiogenesis depending on the time point of
expression during tumor angiogenesis and vasculogene-
sis as well as the availability of the substrates. The key

players of the MMP family that participate in tumor
angiogenesis are mainly MMP-2, -9 and MMP-14,
and, to a lesser extent, MMP-1 and -7 [34].
For cancer cells to continue to grow and start
migrating, it is necessary to form new blood vessels.
The first step in this process is to eliminate the physical
barriers by ECM degradation and, subsequently, to
generate pro-angiogenic factors. Indeed, MMP-9 par-
ticipates in the angiogenic switch because it increases
the biovailability of important factors in this process,
such as the vascular endothelial growth factor
(VEGF), which is the most potent mediator of tumor
vasculature, and basic fibroblast growth factor
(bFGF), by degradation of extracellular components,
such as collagen type IV, XVIII and perlecan, respec-
tively [35–38].
The angiogenic balance is tightly regulated by
MMPs because they can also down-regulate blood ves-
sel formation through the generation of degradation
fragments that inhibit angiogenesis. Such molecules
include tumstatin, endostatin, angiostatin and endore-
pellin, which are generated via cleavage of type IV,
XVII collagen, plasminogen, an inactive precursor of a
serine proteinase plasmin, and perlecan [38–41].
MMPs and cell adhesion, migration, and
epithelial to mesenchymal transition
Cell movement is highly related to the proteolytic
activity of MMPs and ADAMs, regulating the
dynamic ECM–cell and cell–cell interactions during
migration. Initially, the generation of cryptic peptides

via degradation of ECM molecules, such as collagen
type IV and laminin-5, promotes the migration of can-
cer cells [35,42]. Several integrins play an active role in
regulation of cell migration because they can serve as
substrates for MMPs [43].
Over-expression of several MMPs (MMP-2, -3, -9,
-13, -14) has been associated with epithelial to mesen-
chymal transition (EMT), a highly conserved and
fundamental process of morphological transition [5].
In particular, during this event, epithelial cells actively
down-regulate cell–cell adhesion systems, lose their
polarity, and acquire a mesenchymal phenotype with
reduced intercellular interactions and increased migra-
tory capacity [44]. The communication between the
cells is disrupted by the shedding of E-cadherin by
ADAM10, leading to disrupted cell adhesion and
induction of EMT, followed by increased cell migra-
tion [23]. MMP-1 and -7 also appear to contribute to
this morphological transition by cleaving E-cadherin
[45]. Recent studies indicate the implication of MMP-
28 in the proteolytic activation of TGF-b, a powerful
inducer of EMT, leading to EMT [46,47].
It is worth noting that the interaction between hyal-
uronan and its major cell surface receptor, CD44,
results in the activation of signaling molecules such as
Ras, Rho, PI-3 kinases and AKT, consequently
promoting cancer progression. A recent study reported
that hyaluronan promotes cancer cell migration and
MMPs as potential targets in malignancy C. Gialeli et al.
20 FEBS Journal 278 (2011) 16–27 ª 2010 The Authors Journal compilation ª 2010 FEBS

increased matrix metalloproteinase secretion, specifi-
cally the increased active form of MMP-2, through
Rho kinase-mediated signaling [48].
MMPs and immune surveillance
The host immune system is capable of recognizing and
attacking cancer cells by recruiting tumor-specific
T-lymphocytes, NK cells, neutrophils and macrophag-
es. By contrast, cancer cells evolve escaping mecha-
nisms using MMPs to acquire immunity.
MMPs shed interleukin-2 receptor-a by the cell sur-
face of T-lymphocytes, thereby suppressing their prolif-
eration [49]. In addition, TGF-b, a significant
suppressor of T-lymphocyte reaction against cancer
cells, is released as a result of MMP activity [50]. Simi-
larly, MMPs decrease cancer-cell sensitivity to NK
cells by generating a bioactive fragment from a1-pro-
teinase inhibitor [51]. A number of studies have also
shown the ability of MMPs to efficiently cleave several
members of the CC (b-chemokine) and CXC
(a-chemokine) chemokine subfamilies or to regulate
their mobilization, affecting leukocyte infiltration and
migration [52,53].
Pharmacological targeting of matrix
metalloproteinases
On the basis of the pivotal roles that MMPs and
ADAMs play in several steps of cancer progression,
the pharmaceutical industry has invested considerable
effort over the past 20 years aiming to develop safe
and effective agents targeting MMPs. In this regard,
multiple MMPIs have been developed, in an attempt

to control the synthesis, secretion, activation and enzy-
matic activity of MMPs.
Several generations of synthetic MMPIs were tested
in phase III clinical trials in humans, including pepti-
domimetics, nonpeptidomimetics inhibitors and tetra-
cycline derivatives, which target MMPs in the
extracellular space [54]. In addition, various natural
compounds have been identified as inhibiting MMPs
[55]. Other strategies of MMP inhibition in develop-
ment involve antisense and small interfering RNA
(siRNA) technology. Antisense strategies are directed
selectively against the mRNA of a specific MMP,
resulting in decrease of RNA translation and down-
regulation of MMP synthesis [55–57]. Despite the
noted low toxicity of these strategies, they are still
immature with respect to the effectiveness of the tar-
geted delivery of oligonucleotides or siRNA to tumor
cancer cells. Categories of the potential matrix metallo-
proteinase inhibitors and their specificities are summa-
rized in Table 2.
Peptidomimetic MMPIs
The first geneneration of MMPIs introduced com-
prised the peptidomimetic. These pseudopeptide deriv-
atives mimic the structure of collagen at the MMP
cleavage site, functioning as competitive inhibitors,
and chelating the zinc ion present at the activation site
[58]. On the basis of the group that binds and chelates
the zinc ion, peptidomimetis are subdivided into
Table 2. Potential matrix metalloproteinase inhibitors.
MMPI Type of drug ⁄ source Enzymes inhibited

Synthetic inhibitors
Batimastat Peptidomimetic MMP-1, -2, -3, -7, -9
Marimastat Peptidomimetic Broad spectrum
Tanomastat (BAY12-9666) Nonpeptidomimetic MMP-2, -3, -9
Prinomastat (AG3340) Nonpeptidomimetic MMP-2, -3, -7, -9, -13
BMS-275291 Nonpeptidomimetic MMP-2, -9
CGS27023A Nonpeptidomimetic MMP-1, -2, -3
Minocycline Chemically modified tetracycline MMP-1, -2, -3
Metastat (COL-3) Chemically modified tetracycline MMP-1, -2, -8, -9, -13
SB-3CT Reform proenzyme structure MMP-2, -9
INCB7839 Small molecule sheddase inhibitor ADAM-10, 17
Off-target inhibitors
Bisphosphonates Analogues of PPi MMP-1, -2, -7, 9, MT1-, MT2MMP
Letrozole Nonsteroidal inhibitor of aromatase MMP-2, -9
Natural inhibitors
Neovastat (AE-941) Extract from shark cartilage MMP-1, -2, -7, -9, -13
Genistein Soy isoflavone MMP-2, -9, MT1-, MT2-, MT3-MMP
C. Gialeli et al. MMPs as potential targets in malignancy
FEBS Journal 278 (2011) 16–27 ª 2010 The Authors Journal compilation ª 2010 FEBS 21
hydroxamates, carboxylates, hydrocarboxylates, sul-
fhydryls and phosphoric acid derivatives. The earliest
representative of this generation and the first MMPI
that entered clinical trials is batimastat (BB-94), a hy-
droxymate derivative with low water solubility and a
broad spectrum of inhibition [59]. To overcome the
solubility factor, marimastat, another hydroxymate-
based inhibitor, was introduced for oral administered.
However, it was also associated with musculoskeletal
syndrome, probably as a result of the broad spectrum
of inhibition [60,61]. In addition, in vitro studies with

batimastat and marimastat showed that they can act
synergistically with TIMP-2 in the promotion of
proMMP-2 activation by MT1-MMP, increasing overall
pericellular proteolysis [62].
Nonpeptidomimetic MMPIs
To improve specificity and oral bioavailability, the
nonpeptidomimetic MMPIs were synthesized on the
basis of the current knowledge of the 3D conformation
of the MMP active site. This generation comprises of
BAY12-9566, prinomastat (AG3340), BMS-275291
and CGS27023A [63]. The latter agent was aborted as
a result of limited efficacy and musculoskeletal side
effects in phase I clinical trials [64]. Musculoskeletal
toxicity has also been reported in clinical trials with
prinomastat and BMS-275291 [65,66].
Chemically modified tetracyclines
Another generation of MMPIs, tetracycline derivatives,
inhibit both the enzymatic activity and the synthesis of
MMPs via blocking gene transcription. Chemically
modified tetracyclines, lacking antibiotic activities, may
inhibit MMPs by binding to metal ions such as zinc and
calcium. This family of inhibitors, including metastat
(COL-3), minocycline and doxycycline, cause limited
systemic toxicity compared to regular tetracyclines. The
chemically modified tetracycline, doxycycline, is cur-
rently the only Food and Drug Administration
approved MMPI for the prevention of periodontitis,
whereas metastat has entered phase II trials for Kaposi’s
sarcoma and brain tumors [67].
Novel mechanism-based inhibitors

A novel inhibitor, SB-3CT, was designed aiming to
selectively bind to the active site of gelatinases (MMP-2
and MMP-9) and reform the proenzyme structure.
Specifically, the fundamental step in the inhibition of
gelatinases by SB-3CT is an enzyme-catalyzed ring
opening of the thirane, giving a stable zinc-thiolate spe-
cies. It was reported to inhibit liver metastasis and
increase survival in mouse models [68].
On the basis of the importance of the ADAM family
in cancer progression, small molecule inhibitors have
been developed, such as INCB7839, and are currently
being tested in clinical trials [69]. Such agents may be
administered as single agents or in combination with
agents that block the EGFR family at EGFR-depen-
dent tumors [70].
Off-target inhibitors of MMPs
There are several other drugs that have been shown to
influence MMPs and other ECM molecules in a benefi-
cial way beyond their primary target. This is the case
for bisphosphonates, analogs of PPi, which inhibit the
function of the mevalonate pathway. Besides the inhi-
bition of osteoclast activity and bone resorption, bis-
phosphonates inhibit the enzymatic activity of various
MMPs [71]. According to data obtained in our labora-
tory (P.G. Dedes and N.K. Karamanos, unpublished
data), certain bisphosphonates show beneficial effects
as a result of altering the expression pattern of
MMPs ⁄ TIMPs by inhibiting and increasing the gene
and protein expression of several MMPs and TIMPs,
respectively, in breast cancer cells.

Another agent that has exhibited inhibitory effects
on MMPs is letrozole, a reversible nonsteroidal inhibi-
tor of P450 aromatase. In particular, letrozole prevents
the aromatase from converting androgens to estrogens,
the most crucial step in the estrogen synthesis pathway
in post-menopausal women, by binding to the heme of
its cytochrome P450 unit. In addition, the gelatinases
(MMP-2 and -9) released by breast cancer cells, as well
as functional invasion in vitro, are considerably sup-
pressed by letrozole in a dose-dependent fashion, limit-
ing the metastatic potential of these cells [72]. The
above observation is in accordance with the results
obtained in the British International Group 1-98 study
showing that letrozole lowers the occurrence of distant
metastases [73].
It is worth noting that estrogen receptor-a suppres-
sion with siRNA in breast cancer cells lines abolishes
the ability of estradiol to up-regulate the expression of
MMP-9, highlighting the importance of signaling by
estrogen receptors in the expression pattern of MMPs
and therefore their potential pharmacological targeting
[74].
Natural inhibitors of MMPs
TIMPs, the natural inhibitors of MMPs, were also
used to block MMPs activity. Although they have
MMPs as potential targets in malignancy C. Gialeli et al.
22 FEBS Journal 278 (2011) 16–27 ª 2010 The Authors Journal compilation ª 2010 FEBS
demonstrated efficacy in experimental models, TIMPs
may exert MMP-independent promoting effects [75].
To avoid the negative results and toxicity issues

raised by the use of synthetic MMPIs, one answer
was provided by the field of natural compounds. One
compound taken into consideration was extracted
from shark cartilage. Oral administration of a stan-
dardized extract, neovastat, exerts anti-angiogenic and
anti-metastatic activities and these effects depend not
only on the inhibition of MMPs enzymatic activity,
but also on the inhibition of VEGF [76]. Another
natural agent that has anticancer effects is genistein,
a soy isoflavonoid structurally similar to estradiol.
Apart from its estrogening and anti-estrogenic prop-
erties, genistein confers tumor inhibition growth
and invasion effects, interfering with the expression
ratio and activity of several MMPs and TIMPs
[77,78].
Challenges and future prospects
MMPs have well-established complex and key roles in
cancer progression. However, in most cases, the agents
targeting MMPs exhibited poor performance in clinical
trials, in contrast to their promising activity in many
preclinical models [79]. There are several possible
explanations for these contradictive outcomes. First,
the failure observed in phase III clinical trials with
respect to MMPIs reaching the endpoints of progres-
sion-free survival and overall survival may be attrib-
uted to no proper subgroup selection, with mostly
endstage disease patients [80]. As is the case for many
anticancer agents, the administration of MMPIs
should be made after thorough consideration of the
specific cancer-types and stages of disease. In particu-

lar, for certain cancer types, especially those where the
stroma is an essential player in carcinogenesis, the inhi-
bition of MMPs is proven to be more effective [81]. In
addition, the timeframe of targeting MMPs differs,
depending on the stage of cancer, because the expres-
sion profile, as well as the activity of MMPs, is not the
same in the early stage compared to advanced cancer
disease. Recent studies show that members of the
MMP family exert different roles at different steps of
cancer progression. As a consequence, the use of
broad-spectrum MMPI raises concerns when certain
MMPs that exert anticancer effects are inhibited. In
this regard, the use of such MMPIs may lead to unsat-
isfying clinical outcomes as a result of the wide range
of MMPs that are inhibited [82]. In addition, toxicity
effects, such as muscolosceletal syndrome, have limited
the maximum-tolerated dose of certain MMPIs, thus
limiting drug efficacy. The challenge is to distinguish
the specific role of individual enzymes in each case
using both widespread gene and tissue microarrays
[83].
Considering all of the above, one of the major
challenges for the future is the development of inhib-
itors or monoclonal antibodies that bind to the
active site of the enzyme and are specific for certain
MMPs, showing little or no cross-reaction with other
MMPs [81]. In this respect, a potent and highly
selective antibody, DX-2400, against the catalytic
domain of MMP-14 was designed with high binding
affinity [84,85]. To further increase the specificity of

MMPIs, the future of drug development comprises
the use of drugs targeting specific exosites [86]. Exo-
sites are binding sites outside the active domain of
the MMPs and are related to substrate selection of
MMPs [87]. Therefore, future drugs targeting less
conserved exosites rather than the catalytic domain
will result in drugs that are both MMP- and sub-
strate-specific. In this respect, a new class of selec-
tives MMPIs, triple-helical transition state analogs, is
introduced, modulating the collagenolytic activity of
MMPIs [88].
In addition, the molecular complexity of cancer
progression suggests that the appropriate combination
of MMPIs with other chemotherapeutic or molecular
targeted agents may play an important role with
respect to increasing drug efficacy. Last, but not
least, imaging activity of specific MMPs in vivo with
probes will make it possible to evaluate the therapeu-
tic efficacy of MMPIs, as well as their activity, at dif-
ferent stages of cancer progression in certain tumors
[89].
Taking into consideration the data presented in the
present minireview, the minireview by Murphy and
Nagase in this same series [90], and knowledge that
enhanced MMP activity may be required to counter-
balance excessive ECM deposition by myofibroblasts
in the tumor microenvironment, as well as the findings
of a recent study [91] reporting amoeboid-like nonpro-
teolytic cell invasion may affect the action of MMPI,
it is concluded that that the pharmacological targeting

of cancer by the development of a new generation of
effective and selective MMPIs is an emerging and
promising area of research.
Acknowledgements
We thank Professor G. N. Tzanakakis (University of
Crete, Greece) and Dr D. Kletsas (NCSR ‘Demokri-
tos’, Greece) for their critical reading and valuable
advice. We apologize to the authors whose work could
not be cited as a result of space limitations.
C. Gialeli et al. MMPs as potential targets in malignancy
FEBS Journal 278 (2011) 16–27 ª 2010 The Authors Journal compilation ª 2010 FEBS 23
References
1 Jemal A, Tiwari RC, Murray T, Ghafoor A, Samueis
A, Ward E, Feuer EJ & Thum MJ (2004) Cancer
statistics. CA Cancer J Clin 54 , 9–29.
2 Kessenbrock K, Plaks V & Werb Z (2010) Matrix
metalloproteinases: regulators of the tumor
microenviroment. Cell 141, 52–67.
3 Page-McCaw A, Ewald AJ & Werb Z (2007) Matrix
metalloproteinases and the regulation of tissue remodel-
ling. Nat Rev Mol Cell Biol 8, 221–233.
4 Parks WC, Wilson CL & Lopez-Boado YS (2004)
Matrix metalloproteinases as modulators of
inflammation and innate immunity. Nat Rev Immunol 4,
617–629.
5 Egeblad M & Werb Z (2002) New functions for the
matrix metalloproteinases in cancer progression. Nat
Rev Cancer 2, 161–174.
6 Nagase H, Visse R & Murphy G (2006) Structure and
function of matrix metalloproteinases and TIMPs.

Cardiovasc Res 69, 562–573.
7 Roy R, Yang J & Moses AM (2009) Matrix
Metalloproteinases as novel biomarkers and potential
therapeutic targets in human cancer. J Clin Oncol 27,
5287–5297.
8 Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM
& Shafie S (1980) Metastatic potential correlates with
enzymatic degradation of basement membrane collagen.
Nature 284, 67–68.
9 Noe
¨
l A, Jost M & Maquoi E (2008) Matrix metallopro-
teinases at cancer tumor-host interface. Semin Cell Dev
Biol 19, 52–60.
10 Murphy G (2008) The ADAMs: signalling scissors in
the tumour microenvironment. Nat Rev Cancer 8, 932–
941.
11 Rocks N, Paulissen G, El Hour M, Quesada F,
Crahay C, Gueders M, Foidart JM, Noel A & Cataldo D
(2008) Emerging roles of ADAM and ADAMTS
metalloproteinases in cancer. Biochimie 90, 369–379.
12 Deryugina IE & Quigley PJ (2006) Matrix metallopro-
teinases and tumor metastasis. Cancer Metastasis Rev
25, 9–34.
13 Ardi VC, Kupriyanova TA, Deryugina EI & Quigley JP
(2007) Human neutrophils uniquely release TIMP-free
MMP-9 to provide a potent catalytic stimulator of
angiogenesis. Proc Natl Acad Sci USA 104, 20262–
20267.
14 Decock J, Hendrickx W, Vanleeuw U, Van Belle V,

Van Huffel S, Christiaens MR, Ye S & Paridaens R
(2008) Plasma MMP1 and MMP8 expression in breast
cancer: protective role of MMP8 against lymph node
metastasis. BMC Cancer 20, 8–77.
15 Korpi JT, Kervinen V, Ma
¨
klin H, Va
¨
a
¨
na
¨
nen A,
Lahtinen M, La
¨
a
¨
ra
¨
E, Ristimaki A, Thomas G,
Ylipalosaari M, A
˚
stro
¨
mPet al. (2008) Collagenase-2
(matrix metalloproteinase-8) plays a protective role in
tongue cancer. Br J Cancer 98, 766–775.
16 El Hour M, Moncada-Pazos A, Blacher S, Masset A,
Cal S, Berndt S, Detilleux J, Host L, Obaya AJ,
Maillard C et al. (2010) Higher sensitivity of Adamts12-

deficient mice to tumor growth and angiogenesis.
Oncogene 29, 3025–3032.
17 Weaver MA (2006) Invadopodia: specialized cell
structures of cancer invasion. Clin Exp Metastasis 23,
97–105.
18 Loechel F, Fox JW, Murphy G, Albrechtsen R &
Wewer UM (2000) ADAM 12-S Cleaves IGFBP-3 and
IGFBP-5 and Is Inhibited by TIMP-3. Biochem Biophys
Res Commun 278, 511–515.
19 Nakamura M, Miyamoto S, Maeda H, Ishii G,
Hasebe T, Chiba T, Asaka M & Ochiai A (2005)
Matrix metalloproteinase-7 degrades all insulin-like
growth factor binding proteins and facilitates insulin-
like growth factor bioavailability. Biochem Biophys Res
Commun 333, 1011–1016.
20 Gialeli Ch, Kletsas D, Mavroudis D, Kalofonos HP,
Tzanakakis GN & Karamanos NK (2009) Targeting
epidermal growth factor receptor in solid tumors:
critical evaluation of the biological importance of
therapeutic monoclonal antibodies. Curr Med Chem 16,
3797–3804.
21 Suzuki M, Raab G, Moses MA, Fernandez CA &
Klagsbrun M (1997) Matrix metalloproteinase-3 releases
active heparin-binding EGF-like growth factor by
cleavage at a specific juxtamembrane site. J Biol Chem
272, 31730–31737.
22 Sahin U, Weskamp G, Kelly K, Zhou H-M,
Higashiyama S, Peschon J, Hartmann D, Saftig P &
Blobel CP (2004) Distinct roles for ADAM10 and
ADAM17 in ectodomain shedding of six EGFR

ligands. J Cell Biol 164, 769–779.
23 Maretzky T, Reiss K, Ludwig A, Buchholz J, Scholz F,
Proksch E, de Strooper B, Hartmann D & Saftig P
(2005) ADAM10 mediates E-cadherin shedding and
regulates epithelial cell-cell adhesion, migration, and
beta-catenin translocation. Proc Natl Acad Sci USA
102, 9182–9187.
24 Mu D, Cambier S, Fjellbirkeland L, Baron JL, Munger
JS, Kawakatsu H, Sheppard D, Broaddus VC &
Nishimura SL (2002) The integrin alpha(v)beta8
mediates epithelial homeostasis through MT1-
MMP-dependent activation of TGF-beta1. J Cell Biol
157, 493–507.
25 Yu Q & Stamenkovic I (2000) Cell surface-localized
matrix metalloproteinase-9 proteolytically activates
TGF-beta and promotes tumor invasion and angiogene-
sis. Genes Dev 14, 163–176.
26 Yu W-H, Woessner JF, McNeish JD & Stamenkovic I
(2002) CD44 anchors the assembly of matrilysin ⁄ MMP-7
with heparin-binding epidermal growth factor precursor
MMPs as potential targets in malignancy C. Gialeli et al.
24 FEBS Journal 278 (2011) 16–27 ª 2010 The Authors Journal compilation ª 2010 FEBS
and ErbB4 and regulates female reproductive organ
remodeling. Genes Dev 16, 307–323.
27 Syrokou A, Tzanakakis G, Tsegenidis T, Hjerpe A &
Karamanos NK (1999) Effects of glycosaminoglycans
on proliferation of epithelial and fibroblast human
malignant mesothelioma cells: a structure–function rela-
tionship. Cell Prolif 32, 85–99.
28 Strand S, Vollmer P, van de Abeelen L, Gottfried D,

Alla V, Heid H, Kuball J, Theobald M, Galle PR &
Strand D (2004) Cleavage of CD95 by matrix metallo-
proteinase-7 induces apoptosis resistance in tumor cells.
Oncogene 23, 3732–3736.
29 Mitsiades N, Yu WH, Poulaki V, Tsokos M & Stam-
enkovic I (2001) Matrix metalloproteinase-7-mediated
cleavage of Fas ligand protects tumour cells from che-
motherapeutic drug cytotoxicity. Cancer Res 61, 577–
581.
30 Kirkin V, Cahuzac N, Guardiola-Serrano F, Huault S,
Lu
¨
ckerath K, Friedmann E, Novac N, Wels WS,
Martoglio B, Hueber AO et al. (2007) The Fas ligand
intracellular domain is released by ADAM10 and
SPPL2a cleavage in T-cells. Cell Death Differ 14, 1678–
1687.
31 Waldhauer I, Goehlsdorf D, Gieseke F, Weinschenk T,
Wittenbrink M, Ludwig A, Stevanovic S, Rammensee
HG & Steinle A (2008) Tumor associated MICA is shed
by ADAM proteases. Cancer Res 68, 6368–6376.
32 Kulik G, Klippel A & Weber MJ (1997) Antiapoptotic
signalling by the insulin-like growth factor I receptor,
phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol
17, 1595–1606.
33 Sympson CJ, Talhouk RS, Alexander CM, Chin JR,
Clift SM, Bissell MJ & Werb Z (1994) Targeted expres-
sion of stromelysin-1 in mammary gland provides evi-
dence for a role of proteinases in branching
morphogenesis and the requirement for an intact

basement membrane for tissue specific gene expression.
J Cell Biol 125, 681–693.
34 Rundhaug EJ (2003) Matrix metalloproteinases, angio-
genesis, and cancer. Clin Cancer Res 9, 551–554.
35 Xu J, Rodriguez D, Petieclere E, Kim JJ, Hangai M,
Moon YS, Davis GE & Brooks PC (2001) Proteolytic
exposure of a cryptic site within collagen type IV is
required for angiogenesis and tumor growth in vivo.
J Cell Biol 154, 1069–1080.
36 Bergers G, Brekken R, McMahon G, Vu TH, Itoh T,
Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z
et al. (2000) Matrix metalloproteinase-9 triggers the
angiogenic switch during carcinogenesis. Nat Cell Biol
2, 737–744.
37 Whitelock JM, Murdoch AD, Iozzo RV & Underwood
PA (1996) The degradation of human endothelial cell-
derived perlecan and release of bound basic fibroblast
growth factor by stromelysin, collagenase, plasmin, and
heparanases. J Biol Chem 271, 10079–10086.
38 Iozzo RV, Zoeller JJ & Nystro
¨
m A (2009) Basement
membrane proteoglycans: modulators par excellence of
cancer growth and angiogenesis. Mol Cells 27, 503–513.
39 O’Reilly MS, Wiederschain D, Stetler-Stevenson WG,
Folkman J & Moses MA (1999) Regulation of angiosta-
tin production by matrix metalloproteinase-2 in a model
of concomitant resistance. J Biol Chem 274, 29568–
29571.
40 Wen W, Moses MA, Wiederschain D, Arbiser JL &

Folkman J (1999) The generation of endostatin is medi-
ated by elastase. Cancer Res 59, 6052–6056.
41 Theocharis AD, Skandalis SS, Tzanakakis GN &
Karamanos NK (2010) Proteoglycan roles in health and
disease: novel proteoglycan roles in malignancy and their
pharmacological targeting. FEBS J 277, 3904–3923.
42 Koshikawa N, Giannelli G, Cirulli V, Miyazaki K &
Quaranta V (2000) Role of cell surface metalloprotease
MT1-MMP in epithelial cell migration over laminin-5.
J Cell Biol 148, 615–624.
43 Baciu PC, Suleiman EA, Deryugina EI & Strongin AY
(2003) Membrane type-1 matrix metalloproteinase
(MT1-MMP) processing of pro-alphav integrin regu-
lates cross-talk between alphavbeta3 and alpha2beta1
integrins in breast carcinoma cells. Exp Cell Res 291,
167–175.
44 Polyak K & Weinberg RA (2009) Transitions between
epithelial and mesenchymal states: acquisition of malig-
nant and stem cell traits. Nat Rev Cancer 9, 265–273.
45 Noe V, Fingleton B, Jacobs K, Crawford HC, Vermeu-
len S, Steelant W, Bruyneel E, Matrisian LM & Mareel
M (2001) Release of an invasion promoter E-cadherin
fragment by matrilysin and stromelysin-1. J Cell Sci
114, 111–118.
46 Illman SA, Lehti K, Keski-Oja J & Lohi J (2006)
Epilysin (MMP-28) induces TGF-beta mediated
epithelial to mesenchymal transition in lung carcinoma
cells. J Cell Sci 119, 3856–3865.
47 Heldin C-H, Landstro
¨

m M & Moustakas A (2009)
Mechanism of TGF-b signaling to growth arrest, apop-
tosis, and epithelial–mesenchymal transition. Curr Opin
Cell Biol 21, 166–176.
48 Torre C, Wang SJ, Xia W & Bourguignon LY (2010)
Reduction of hyaluronan-CD44-mediated growth,
migration, and cisplatin resistance in head and neck
cancer due to inhibition of Rho kinase and PI-3 kinase
signaling. Arch Otolaryngol Head Neck Surg 136(5),
493–501.
49 Sheu B-C, Hsu S-M, Ho H-N, Lien H-C, Huang S-C &
Lin R-H (2001) A novel role of metalloproteinase in
cancer-mediated immunosuppression. Cancer Res 61,
237–242.
50 Gorelik L & Flavell RA (2001) Immune-mediated
eradication of tumors through the blockade of
transforming growth factor-b signaling in T cells. Nat
Med 7, 1118–1122.
C. Gialeli et al. MMPs as potential targets in malignancy
FEBS Journal 278 (2011) 16–27 ª 2010 The Authors Journal compilation ª 2010 FEBS 25
51 Kataoka H, Uchino H, Iwamura T, Seiki M, Nabeshi-
ma K & Koono M (1999) Enhanced tumor growth and
invasiveness in vivo by a carboxyl-terminal fragment of
a1-proteinase inhibitor generated by matrix metallopro-
teinases: a possible modulatory role in natural killer
cytotoxicity. Am J Pathol 154, 457–468.
52 Li Q, Park PW, Wilson CL & Parks WC (2002)
Matrilysin shedding of syndecan-1 regulates chemokine
mobilization and transepithelial efflux of neutrophils in
acute lung injury. Cell 111, 635–646.

53 Balbin M, Fueyo A, Tester AM, Pendas AM, Pitiot AS,
Astudillo A, Overall CM, Shapiro SD & Lopez-Otin C
(2003) Loss of collagenase-2 confers increased skin
tumor susceptibility to male mice. Nat Genet 35, 252–
257.
54 Mannello F, Tonti G & Papa S (2005) Matrix metallo-
proteinase inhibitors as targets of anticancer therapeu-
tics. Curr Cancer Drug Targets 5, 285–298.
55 Mannello F (2006) Natural bio-drugs as matrix metallo-
proteinase inhibitors: new perspectives on the horizon?
Recent Pat Anticancer Drug Discov 1, 91–103.
56 Jiang X, Dutton CM, Qi W, Block JA, Brodt P,
Durko M & Scully SP (2003) Inhibition of MMP-1
expression by antisense RNA decreases invasiveness of
human chondrosarcoma. Orthop Res 21, 1063–1070.
57 Jiang X, Dutton CM, Qi WN, Block JA, Garamszegi N
& Scully SP (2005) siRNA mediated inhibition of
MMP-1 reduces invasive potential of a human chondro-
sarcoma cell line. J Cell Physiol 202, 723–730.
58 Betz M, Huxley P, Davies SJ, Mushtaq Y, Pieper M,
Tschesche H, Bode W & Gomis-Ru
¨
th FX (1997) 1.8-
Acrystal structure of the catalytic domain of human
neutrophil collagenase (matrix metalloproteinase-8)
complexed with a peptidomimetic hydroxamate primed-
side inhibitor with a distinct selectivity profile. Eur J
Biochem 247, 356–363.
59 Macaulay VM, O’Byrne KJ, Saunders MP, Braybrooke
JP, Long L, Gleeson F, Mason CS, Harris AL, Brown

P & Talbot DC (1999) Phase I study of intrapleural
batimastat (BB-94), a matrix metalloproteinase inhibi-
tor, in the treatment of malignant pleural effusions. Clin
Cancer Res 5, 513–520.
60 Steward WP & Thomas AL (2000) Marimastat: the
clinical development of a matrix metalloproteinase
inhibitor. Expert Opin Investig Drugs 9, 2913–2922.
61 Sparano JA, Bernardo P, Stephenson P, Gradishar WJ,
Ingle JN, Zucker S & Danidson NE (2004) Randomized
phase III trial of marimastat versus placebo in patients
with metastatic breast cancer who have responding or
stable disease after first-line chemotherapy: Eastern
Cooperative Oncology Group trial E2196. J Clin Oncol
22, 4683–4690.
62 Toth M, Bernardo MM, Gervasi DC, Soloway PD,
Wang Z, Bigg HF, Overall CM, DeClerck YA,
Tschesche H, Cher ML et al. (2000) Tissue inhibitor of
metalloproteinase (TIMP)-2 acts synergistically with
synthetic matrix metalloproteinase (MMP) inhibitors
but not with TIMP-4 to enhance the (membrane type
1)-MMP-dependent activation of pro-MMP-2. J Biol
Chem 275, 41415–41423.
63 Brown PD (2000) Ongoing trials with matrix metallo-
proteinase inhibitors. Expert Opin Investig Drugs 9,
2167–2177.
64 Levitt NC, Eskens FA, O’Byrne KJ, Propper DJ,
Denis LJ, Owen SJ, Choi L, Foekens JA, Wilner S,
Wood JM et al. (2001) Phase I and pharmacological
study of the oral matrix metalloproteinase inhibitor,
MMI270 (CGS27023A), in patients with advanced solid

cancer. Clin Cancer Res 7, 1912–1922.
65 Hidalgo M & Eckhardt SG (2001) Development of
matrix metalloproteinase inhibitors in cancer therapy.
J Natl Cancer Inst 93, 178–193.
66 Miller KD, Saphner TJ, Waterhouse DM, Chen TT,
Rush-Taylor A, Sparano JA, Wolff AC, Cobleigh MA,
Galbraith S & Sledge GW (2004) A randomized phase
II feasibility trial of BMS-275291 in patients with early
stage breast cancer. Clin Cancer Res 10, 1971–1975.
67 Sapadin AN & Fleischmajer R (2006) Tetracyclines:
nonantibiotic properties and their clinical implications.
J Am Acad Dermatol 54, 258–265.
68 Kruger A, Arlt MJ, Gerg M, Kopitz C, Bernardo MM,
Chang M, Mobashery S & Fridman R (2005) Antimeta-
static activity of a novel mechanism-based gelatinase
inhibitor. Cancer Res 65, 3523–3526.
69 Moss ML & Bartsch JW (2004) Therapeutic benefits
from targeting of ADAM family members. Biochemistry
43, 7227–7235.
70 Fridman JS, Caulder E, Hansbury M, Liu X, Yang G,
Wang Q, Lo Y, Zhou BB, Pan M, Thomas SM et al.
(2007) Selective inhibition of ADAM metalloproteases
as a novel approach for modulating ErbB pathways in
cancer. Clin Cancer Res 13, 1892–1902.
71 Coxon FP, Thompson K & Rogers MJ (2006) Recent
advances in understanding the mechanism of action of
bisphosphonates. Curr Opin Pharmacol 6, 307–312.
72 Mitropoulou TN, Tzanakakis GN, Kletsas D, Kalofo-
nos HP & Karamanos NK. (2003) Letrozole as a
potent inhibitor of cell proliferation and expression of

metalloproteinases (MMP-2 and MMP-9) by human
epithelial breast cancer cells. Int J Cancer 104,
155–160.
73 Thu
¨
rlimann B, Keshaviah A, Coates AS, Mouridsen H,
Mauriac L, Forbes JF, Paridaens R, Castiglione-Ger-
tsch M, Gelber RD, Rabagli M et al. (2005) A compari-
son of letrozole and tamoxifen in postmenopausal
women with early breast cancer. N Engl J Med 353,
2747–2757.
74 Kousidou OCh, Berdiaki A, Kletsas D, Zafiropoulos A,
Theocharis AD, Tzanakakis GN & Karamanos NK
(2008) Estradiol–estrogen receptor: a key interplay of
MMPs as potential targets in malignancy C. Gialeli et al.
26 FEBS Journal 278 (2011) 16–27 ª 2010 The Authors Journal compilation ª 2010 FEBS
the expression of syndecan-2 and metalloproteinase-9 in
breast cancer cells. Mol Oncol 2, 223–232.
75 Brew K & Nagase H (2010) The tissue inhibitors of
metalloproteinases (TIMPs): an ancient family with
structural and functional diversity. Biochim Biophys
Acta 1803, 55–71.
76 Falardeau P, Champagne P, Poyet P, Hariton C &
Dupont E (2001) Neovastat, a natutally occuring
multifunctional antiangiogenic drug, in phase III clinical
trials. Semin Oncol 28, 620–625.
77 Huang X, Chen S, Xu L, Liu Y, Deb DK, Platanias
LC & Bergan RC (2005) Genistein inhibits p38 map
kinase activation, matrix metalloproteinase type 2, and
cell invasion in human prostate epithelial cells. Cancer

Res 65, 3470–3478.
78 Kousidou OC, Mitropoulou TN, Roussidis AE, Kletsas
D, Theocharis AD & Karamanos NK (2005) Genistein
suppresses the invasive potential of human breast
cancer cells through transcriptional regulation of metal-
loproteinases and their tissue inhibitors. Int J Oncol 26,
1101–1109.
79 Fingleton B (2008) MMPs as therapeutic targets–still a
viable option? Semin Cell Dev Biol 19, 61–68.
80 Bergers G, Javaherian K, Lo KM, Folkman J &
Hanahan D (1999) Effects of angiogenesis inhibitors
on multistage carcinogenesis in mice. Science 284,
808–812.
81 Konstantinopoulos PA, Karamouzis MV, Papatsoris
AG & Papavassiliou AG (2008) Matrix Metalloprotein-
ase inhibitors as anticancer agents. Int J Biochem & Cell
Biol 40, 1156–1168.
82 Lopez-Otin C & Matrisian LM (2007) Emerging roles
of proteases in tumour suppression. Nat Rev Cancer 7,
800–808.
83 Murphy G & Nagase H (2008) Progress in matrix
metalloproteinases research. Mol Aspects Med 29,
290–308.
84 Cuniasse P, Dev L, Makaritis A, Beau F, Georgiadis
D, Matziari M, Yiotakis A & Dive V (2005) Future
challenges facing the development of specific active-site
directed synthetic inhibitors of MMPs. Biochimie 87,
393–402.
85 Devy L, Huang L, Naa L, Yanamandra N, Pieters H,
Frans N, Chang E, Tao Q, Vanhove M, Lejeune A

et al. (2009) Selective inhibition of matrix metallopro-
teinase-14 blocks tumor growth, invasion, and angio-
genesis. Cancer Res 69, 1517–1526.
86 Hadler-Olsen E, Fadness B, Sylte I, Uhlin-Hansen L &
Winberg JO (2010) Regulation of matrix metallo-
proteinase activity in health and disease. FEBS J 278,
28–45.
87 Overall CM (2002) Molecular determinants of metallo-
proteinase substrate specificity: matrix metalloproteinas-
es and new ‘intracellular’ substrate binding domains,
modules and exosites. Mol Biotechnol Chem 383, 1059–
1066.
88 Lauer-Fields J, Brew K, Whitehead JK, Li S, Ham-
mer RP & Fields GB (2007) Triple-helical transition
state analogues: a new class of selective matrix metal-
loproteinase inhibitors. J Am Chem Soc 129, 10408–
10417.
89 Bremer C, Tung CH & Weissleder R (2001) In vivo
molecular target assessment of matrix metalloproteinase
inhibition. Nat Med 7, 743–748.
90 Murphy G & Nagase H (2010) Localising MMP activi-
ties in the pericellular environment. FEBS J
278, 2–15.
91 Friedl P & Wolf K (2010) Plasticity of cell migration: a
multiscale tuning model. J Cell Biol 188, 11–19.
C. Gialeli et al. MMPs as potential targets in malignancy
FEBS Journal 278 (2011) 16–27 ª 2010 The Authors Journal compilation ª 2010 FEBS 27